06.04.2023

Eurogentec: €14Mio invested to increase mRNA production fivefold

With its experience in gene therapy, Kaneka intends to meet the growing needs of the market by investing €14Mio in its Belgian subsidiary, the biotechnology company Eurogentec, in order to increase its messenger RNA production capacity fivefold by 2024. This investment consolidates Wallonia's strategic positioning in GMP Plasmid DNA and mRNA biomanufacturing for vaccines & therapeutics worldwide.

Already new labs for plasmid and protein processes optimization

With its brand new Process Transfer & Development labs, Eurogentec now has 10,750 ft² dedicated to the optimization of plasmid and protein processes. These labs are equipped with all scales of fermenters, from the very small scale of the Ambr system to 5L, 30L and 50L fermenters, various lysis and purification equipment, and all the required QCs, to ensure smooth transition and scale-up from development to the GMP production area.

Eurogentec’s new production facility to open in 2024

"We see an acceleration in this market. We need to invest to meet the higher expectations of our customers and to serve new customers", said Lieven Janssens, Managing Director of Kaneka Eurogentec, which plans to put the new production plant into operation in 2024. This investment will create 10 to 20 additional jobs. It currently employs 430 people. "We have doubled in size in six years", he says.

Sources: lecho.be & eurogentec.com

For more information about Eurogentec Kaneka GMP Plasmid DNA/mRNA platform, click here.

GSK and imec to collaborate on disruptive innovation in pharma

A collaboration between GSK, a multinational pharma company whose vaccines headquarters are in Wallonia, and imec, a leading nanoelectronics research centre based in Flanders, is bringing together in Belgium two of its most innovative sectors...

Work-study programs: a springboard to biomanufacturing jobs?

Wallonia is developing new work-study programs to enable students to learn biomanufacturing both through teaching and experience in the workplace.

UCB invests in a bioproduction plant in Braine-l’Alleud

To support the launch of a new generation of products, UCB, the biopharmaceutical company specialized in neurology and immunology, is investing 300 million euros in the construction of an ultra-modern biological production plant at its site in Braine-l’Alleud...

Interested in updates on our insights, news and testimonials?